Advertisement

Topics

T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)

11:00 EDT 15 Jul 2017 | MedPageToday

(MedPage Today) -- 41% of HER2+/HR+ patients achieved a pathologic complete response

Original Article: T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)"

Quick Search
Advertisement